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Summary points
• The landscape of tuberculosis (TB) treatment has evolved considerably over the last 10
years, necessitating careful consideration of various trial design aspects to ensure that
TB phase III trials are still impactful at trial completion, often more than 4–5 years after
initial design.
• The choice of control is guided by the specific trial objectives, weighing the relative mer-
its of internal validity and external generalizability alongside randomization in making
the correct inference. A particular challenge occurs when international or national
guidelines change during the trial.
• Improved execution and relevance of noninferiority trials for TB require greater empha-
sis on study quality, especially maximizing treatment adherence and minimizing miss-
ing outcome data; preferred use of intention-to-treat rather than per-protocol analyses;
more careful justification of the margin of noninferiority; and consideration of recent
innovations such as a Bayesian approach to noninferiority.
• Many adaptive trial designs are well suited to optimization of TB treatment. A thorough
understanding of type I error rates and biases in treatment effect estimates is critical for
regulatory approval and consideration in establishing World Health Organization
(WHO) guidelines.
• Treatment stratification is an area of limited experience for TB trials, and trialists must
learn from well-established methodology in other disease areas.
• Explanatory trials are important for evaluating the efficacy of an intervention under
close to ideal conditions. However, no single trial can address all relevant questions
about a given therapeutic intervention at one time, and pragmatic trials will be essential
for public health and policy decision-making purposes.
• TB treatment trials today should favor bold and creative approaches that can produce
high-quality evidence for effective, patient-centered care made accessible to all 10 million
new TB patients, including the half-million with drug-resistant TB (DR-TB), each year.
PLOS Medicine | https://doi.org/10.1371/journal.pmed.1002767 March 22, 2019 1 / 15
a1111111111
a1111111111
a1111111111
a1111111111
a1111111111
OPEN ACCESS
Citation: Phillips PPJ, Mitnick CD, Neaton JD,
Nahid P, Lienhardt C, Nunn AJ (2019) Keeping
phase III tuberculosis trials relevant: Adapting to a
rapidly changing landscape. PLoS Med 16(3):
e1002767. https://doi.org/10.1371/journal.
pmed.1002767
Published: March 22, 2019
Copyright: © 2019 World Health Organization.
Licensee Public Library of Science. This is an open
access article distributed under the Creative
Commons Attribution IGO License, which permits
unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly
cited. http://creativecommons.org/licenses/by/3.0/
igo/. In any use of this article, there should be no
suggestion that WHO endorses any specific
organization, products or services. The use of the
WHO logo is not permitted. This notice should be
preserved along with the article’s original URL.
Funding: The authors received no specific funding
for this work.
Competing interests: The authors have declared
that no competing interests exist.
Abbreviations: DR-TB, drug-resistant TB; DS-TB,
drug-sensitive TB; DSMB, data and safety
monitoring board; EMA, European Medicines
Agency; FDA, Food and Drug Administration; GCP,
Good Clinical Practice; ICH, International Council
for Harmonization of Technical Requirements for
Introduction
One of the first multicenter randomized trials was the British Medical Research Council
(MRC) streptomycin trial [1]. From the first meeting of the special committee to “plan trials of
streptomycin in tuberculosis” in September, 1946, the primary trial results from 107 partici-
pants followed for 12 months were published in the British Medical Journal two years later in
October, 1948 [2]. Although treatment with a single drug was subsequently shown to be inade-
quate because of the generation of drug resistance [3], the results of the trial changed clinical
practice [1].
It has, however, become difficult to conduct phase III clinical trials in the 21st century in
any disease area in such a short time frame. Trials often require more patients to show benefit,
and their initiation is often protracted because of the need for independent ethical review(s),
approval by national regulatory bodies, and the training and compliance with Good Clinical
Practice (GCP) that is necessary to ensure that the trial is designed and conducted to the high-
est standards. All of these changes have been aimed, rightly, at protecting participants and
ensuring reliable results, but they have also limited the ability to conduct clinical trials to
respond quickly to important public health questions, especially in the context of a rapidly
evolving disease and treatment landscape. The interval from start of enrollment to first public
presentation of results of recent phase III tuberculosis (TB) trials ranges from 4.6–8.4 years [4–
7]. This does not include time for design, planning, and ethical and regulatory approvals prior
to start of recruitment, which commonly takes at least a year, and is consistent with a system-
atic review of time to publication of results across other disease areas [8].
The landscape of TB treatment has evolved considerably over the last 10 years—particularly
in the management of drug-resistant TB (DR-TB). Changes include the earlier diagnosis of
DR-TB with widespread implementation of newer tests such as GeneXpert [9,10] and Line
Probe Assays [11], a better understanding of the pharmacology and bactericidal activity of the
various drugs used [12], and the introduction of new drugs (bedaquiline with accelerated
approval by the United States Food and Drug Administration [FDA] in December, 2012 and
delamanid with conditional approval by the European Medicines Agency [EMA] in Novem-
ber, 2013), as well as observational studies and clinical trials investigating various combina-
tions of current, new, and repurposed drugs in an attempt to shorten DR-TB therapies [13–
17]. These developments are reflected in evolving World Health Organization (WHO) guid-
ance for DR-TB (see Table 1). Furthermore, knowledge about the epidemic itself continues to
evolve with a recognition of the growing importance of the transmission of DR-TB [18,19] and
increasing levels of second-line drug resistance [20]. Thus, in 2017, among the 10.0 million
people developing TB disease, 558,000 (5.6%) developed a form that was resistant to at least
rifampicin, the most effective first-line drug, and 230,000 died of it. The severity of national
epidemics varies widely among countries. Estimated prevalence of rifampicin-resistant TB
(RR-TB) among new TB cases ranges from 1.3% in Kenya to 38.0% in Belarus among the 30
high-TB–burden countries [20].
Given the unavoidably protracted duration of phase III TB trials in the 21st century, the sta-
tus of TB as a global health priority (the first ever United Nations [UN] General Assembly
high-level meeting on TB was held in September, 2018), and the increasing trial costs relative
to a huge shortfall in research and development funding [21], those who conduct clinical trials
are obligated to design them in such a way that they will have a direct impact on policy and
practice of TB treatment at the projected time of trial completion. In this paper, as part of a
PLOS Medicine Collection on Advances in Clinical Trial Design for Development of New TB
Treatments [22], we discuss how phase III TB trials could be designed with such “future-proof-
ing” in mind.
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Choice of control
It is usual for the comparator in a clinical trial to be the standard of care treatment so that the
results can be interpreted in relation to current practice [23]. Furthermore, the principle of
clinical equipoise provides an ethical obligation to ensure patients on the control arm receive
the best available standard of care [24]. In drug-sensitive TB (DS-TB), a 6-month regimen of
rifampicin and isoniazid, supplemented by pyrazinamide and ethambutol in the first 2
months, is the recognized standard of care [25]; all recent phase III trials have therefore used
Table 1. Summary of WHO guidelines, policies, and statements on the treatment of DR-TB. Guidelines for the treatment of DS-TB are not included because these
have remained largely unchanged in this period. Key dates are also included from the case study of the STREAM trial, a trial comparing a 9- to 11-month regimen contain-
ing high-dose moxifloxacin and clofazimine with the 20- to 24-month WHO-recommended standard of care regimen for MDR-TB, which is discussed further in Box 1.
Key event in STREAM trial Date of publication
or event
WHO document title
1996 Guidelines for the management of multidrug-resistant tuberculosis
2000 Guidelines for establishing DOTS-Plus pilot projects for the management of multidrug-
resistant tuberculosis (MDR-TB)
2006 Guidelines for the programmatic management of drug-resistant tuberculosis
2008 Guidelines for the programmatic management of drug-resistant tuberculosis.
Emergency Update 2008
June, 2011 Guidelines for the programmatic management of drug-resistant tuberculosis. 2011
update
First participant enrolled in STREAM Stage 1 trial July, 2012
June, 2013 The use of bedaquiline in the treatment of multidrug-resistant tuberculosis: Interim
policy guidance
October, 2014 The use of delamanid in the treatment of multidrug-resistant tuberculosis: Interim
policy guidance
Last participant enrolled in STREAM Stage 1 trial June, 2015
First participant enrolled in STREAM Stage 2 trial April, 2016
May, 2016 WHO treatment guidelines for drug-resistant tuberculosis. 2016 update
October, 2016 WHO treatment guidelines for drug-resistant tuberculosis. 2016 update. October 2016
revision
October, 2016 The use of delamanid in the treatment of multidrug-resistant tuberculosis in children
and adolescents: Interim policy guidance
March, 2017 Report of the Guideline Development Group Meeting on the use of bedaquiline in the
treatment of multidrug-resistant tuberculosis. A review of available evidence (2016)
Preliminary results from STREAM Stage 1 trial
presented at 48th Union Conference on Lung Health
October, 2017
January, 2018 WHO position statement on the use of delamanid for multidrug-resistant tuberculosis
March, 2018 WHO treatment guidelines for isoniazid-resistant tuberculosis: Supplement to the
WHO treatment guidelines for drug-resistant tuberculosis
April, 2018 Position statement on the continued use of the shorter MDR-TB regimen following an
expedited review of the STREAM Stage 1 preliminary results
August, 2018 Rapid Communication: Key changes to treatment of multidrug- and rifampicin-
resistant tuberculosis (MDR/RR-TB)
Final results from STREAM Stage 1 trial presented at
49th Union Conference on Lung Health
October, 2018
December, 2018 WHO treatment guidelines for multidrug- and rifampicin-resistant tuberculosis. 2018
update. Pre-final text
Expected early 2019 WHO treatment guidelines for multidrug- and rifampicin-resistant tuberculosis. Final
text
Abbreviations: DS-TB, drug-sensitive tuberculosis; MDR-TB, multidrug-resistant tuberculosis; RR-TB, rifampicin-resistant tuberculosis; TB, tuberculosis; WHO,
World Health Organization.
https://doi.org/10.1371/journal.pmed.1002767.t001
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this regimen as the internal control. For DR-TB, WHO guidelines provide a recipe for con-
structing an effective regimen based on the combination of drugs from various classes, leading
to variability in terms of regimen composition across patients and trial sites. The most recent
guidelines go further and recommend both long and short regimens [26]. For these reasons,
and in the absence of an established standard, trials have selected various approaches to the
choice of control (see Table 2 for a discussion of advantages and limitations). For example, the
design that adds a single new drug (or placebo) to a background regimen has shown its limita-
tions because it provides no information on the optimal regimen within which the new drug
can be used. The specific trial objectives will guide the choice of control, weighing the relative
merits of internal validity and external generalizability alongside randomization in making the
correct inference [27]. In any case, the implications of each approach on the trial’s statistical
considerations as well as the final interpretation of the trial results need to be carefully consid-
ered from the outset.
Table 2. Controls used in DR-TB trials.
Choice of control Examples Strengths Limitations
Placebo, added to optimized
background regimen
Delamanid phase II and
III trials [28,29]
Bedaquiline phase II trial
[30,31], Opti-Q [32]
Permits blinding of healthcare providers and
participants, yielding unbiased estimates of the
efficacy and safety of the individual drug. This
design was used to inform regulatory approval of
new drugs.
Yields little or no information on how to use the
drug in a regimen, which is essential for
programmatic implementation; effect of drug can be
masked if background regimen is highly effective.
External control (historical or
concurrent)
NiX-TB (NCT02333799),
ZeNiX-TB
(NCT03086486)
Smaller sample size and operational efficiencies
due to absence of randomization and use of only
one regimen. Considered the only option if there
is no accepted standard of care. The justification
for use of a historic control can only be used in the
first successful trial in that patient population;
subsequent trials could use the previous
intervention as internal control.
Highly dependent on choice of external control,
differences between patient populations and secular
trends (with a historical control) affect
interpretation of results. Challenging to quantify
how much “supportive care” in the trial affected
outcomes relative to control outside trial [33].
Randomized comparison in
DS-TB, parallel uncontrolled
DR-TB cohort with same
regimen
STAND (NCT02342886),
SimpliciTB
(NCT03338621)
Randomized comparison in DS-TB provides
strong evidence for safety of regimen in TB
patients and efficacy in DS-TB. The parallel
DR-TB cohort informs whether results differ
between the two TB patient populations.
Only appropriate for regimens that are targeted for
both DS- and DR-TB. Extrapolation from DS-TB
comparison to DR-TB population requires
assumptions.
Local standard of care (varying
by site)
STREAM Stage 1 [34],
endTB [35]
Better external validity because of randomization
to genuine standard of care, operational
efficiencies because sites use local standard for
control arm participants.
Control regimen may differ by site and over time.
This will increase variability in results and may need
to be accounted for by increasing sample size.
Prescriptive regimen NEXT (NCT02454205),
STREAM Stage 2 [36]
Better internal validity because of clear
randomized comparison of two regimens.
Limited external validity since choice of control
regimen may not reflect standard in many places.
This would change if a standardized regimen is
widely adopted; there are currently variations in
how the short regimen is used (for example, choice
of fluoroquinolone and bedaquiline in South
Africa).
Abbreviations: DR-TB, drug-resistant TB; DS-TB, drug-sensitive TB; TB, tuberculosis.
https://doi.org/10.1371/journal.pmed.1002767.t002
Box 1. A case study: The STREAM trial [34,36]
The STREAM trial was initiated to evaluate a novel 9- to 11-month regimen for the
treatment of multidrug-resistant TB (MDR-TB) based on results from an observational
cohort study in Bangladesh [13,16]. The primary objective of Stage 1 of this multicenter
randomized trial was to determine whether a slightly modified version of this regimen
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(with high-dose moxifloxacin replacing gatifloxacin) was safe and at least as effective as
the recommended standard of care. The first trial participant was enrolled in July, 2012,
with the first results due to be published in 2019. During the trial period, the landscape
changed substantially (as described in main text), and the trial had to adapt in a number
of ways.
Incorporating new drugs in additional trial arms
The availability of new drugs without data on how to use them in combination regimens
prompted the investigators to consider transitioning from a two-arm study (STREAM
Stage 1) to a four-arm study (STREAM Stage 2), with the aim that any new arm(s) added
to the trial should be shorter or simpler to take and intended to be less toxic. Through
wide consultation, an injectable-sparing regimen to avoid the hearing loss associated
with aminoglycoside use was selected. There was also preference for a regimen that
excluded prothionamide and ethionamide because these drugs cause nausea and vomit-
ing that compromise the tolerability of any MDR-TB regimen. The decision was there-
fore made to add four arms, a 9-month completely oral regimen in which kanamycin
was replaced by bedaquiline and a shorter 6-month regimen in which bedaquiline
replaced prothionamide and kanamycin duration was reduced to 8 weeks. The primary
objective of Stage 2 was to evaluate whether the bedaquiline-containing regimens were
safe with efficacy not inferior to that of the 9- to 11-month control regimen.
The first patient in Stage 2 was randomized in April, 2016. In order to ensure timely
completion of the main comparison of the fully oral regimen with the 9- to 11-month
injectable-containing regimen and the increasing desirability of an injection-free regi-
men, it was decided to terminate enrollment to the 6-month injectable-containing regi-
men in 2018.
Choice of control
The locally used 20- to 24-month regimen consistent with 2011 WHO guidelines [39]
was selected as the control arm in Stage 1. Although results from Stage 1 were not avail-
able at the time that Stage 2 was initiated, the STREAM investigators took the unconven-
tional step of including two control regimens: (i) the 9- to 11-month regimen studied as
the intervention in Stage 1 and (ii) the locally used WHO-recommended regimen that
had been the control in Stage 1. The second control was considered as a “reserve internal
control.” Although it was not included in the primary objective and only 1 in 7 partici-
pants were to be allocated to this arm, it was to be used as a comparator in secondary
analyses to permit interpretation of the results of the trial as compared to 2011 WHO
guidelines.
In May, 2016, the revised MDR-TB treatment guidelines from WHO recommended a
short regimen very similar to that being evaluated in the STREAM trial (see Table 1) for
patients who met specific inclusion criteria. Subsequently, countries adopting these
revised guidelines were no longer able to enroll patients to the second control arm. The
protocol was therefore amended to exclude enrollment to the “reserve internal control”
in these countries, thereby unfortunately reducing the value of comparisons to that regi-
men because of fewer participants.
Continued evolution in WHO guidance [26], and its implications for the control arm, is
under consideration by the investigators.
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An added complication arises when international or national guidelines change during the
course of a trial, as exemplified in the STREAM trial [34,36] (see Box 1). If significant new
developments arise during the course of a trial that may impact a participant’s willingness to
continue, investigators have a responsibility to inform patients; this is part of the Federal Code
of Regulations in the US. It may not be feasible or ethical to continue the trial without modifi-
cation under such circumstances; conversely, if the evidence base for change is weak [37] and
randomization among treatment arms is still possible, no change in the trial design may be
warranted [38]. The investigators, usually with advice of an independent group such as the
data and safety monitoring board (DSMB) or a community advisory group, should evaluate
the new information and make a judgment about whether the trial protocol should be modi-
fied and how, if at all, participants should be informed. Policy makers and guideline developers
can help with this by including explicit wording that further research is still needed when mak-
ing recommendations that are based on low certainty in the evidence.
Noninferiority, analysis populations, and “estimands”
Noninferiority trials are designed to evaluate whether a reduction in efficacy with the interven-
tion as compared to the control does not exceed a prespecified threshold. The prespecified dif-
ference is denoted as the noninferiority margin (see Fig 1 for an illustration of the results of a
noninferiority trial). The choice of the margin in trials of TB treatment regimens continues to
be a major discussion issue. In order to have confidence that the new treatment is better than
no treatment, it is accepted that the margin should be no larger, and considerably smaller,
than the estimate of benefit of the chosen control as compared to no treatment. This effect is,
however, estimated from historical data [41], and the statistical uncertainty of the estimate
should be taken into account. For example, a somewhat conservative estimate of the success
rate of standard therapy in DS-TB is around 85% [42], which, compared to the estimated 30%
survival from untreated TB [43], gives an estimate of an absolute treatment effect of 55%. A
declaration of noninferiority with a margin of 10% would therefore give confidence that more
than 80% of this effect of the control is preserved, and 90% would be preserved with a margin
of 5%.
Consideration of the expected benefits of the intervention shapes the final choice of margin.
In TB, regimens that are shorter confer a direct benefit to patients and health systems. They
are expected to result in better treatment adherence in addition to reduced patient and health
Balancing program and regulatory objectives
The primary aim of the trial is to evaluate the efficacy and safety of new regimens for
MDR-TB. The 9- to 11-month all-oral regimen in STREAM Stage 2 is the same as the 9-
to 11-month control, except that kanamycin is replaced with bedaquiline. The compari-
son of these two regimens is therefore a randomized comparison of bedaquiline to kana-
mycin within a multidrug combination.
This is quite different from the add-on trial with the placebo comparison used in the piv-
otal phase II trial of bedaquiline [31,40] (see the first row in Table 2) because it provides
evidence both of the efficacy and safety of new standardized regimens that include beda-
quiline as well as of the long-term efficacy and safety of bedaquiline, albeit in compari-
son to kanamycin rather than placebo. With this, it has become the confirmatory phase
III trial to be considered by the FDA following the accelerated approval of bedaquiline.
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system costs, although none of these can be easily measured in a clinical trial that is not close
to usual practice. Anticipated reduction in toxicity is another factor that may influence the
choice of margin; whether this is a consequence of the new treatment or not cannot be known
until the trial has been completed. Collection of good safety data is critical to properly weigh
the risks and benefits of an intervention. Combining efficacy and safety in a composite out-
come or a formal risk–benefit scoring system [44] is useful to summarize this balance in a sin-
gle measure. Such measures can, however, obscure differences between outcomes of varying
severity. Papers summarizing the primary results of trials should, therefore, report safety and
efficacy outcomes separately for others to make a judgment on the risk–benefit balance.
There has been a trend towards larger noninferiority margins in a number of recent proto-
cols; this permits a reduction in sample size, resulting in a less expensive study and earlier
completion, but leads to greater uncertainty as to the true efficacy of the regimen. Widening
the margin increases the possibility that a substandard regimen could be accepted as a new
gold standard, thereby increasing the risk of “biocreep,” whereby after several generations of
noninferiority trials, considerably less effective regimens would become the standard of care
simply because of the cumulative reduction in efficacy [45,46].
The intention-to-treat (ITT) analysis population includes all randomized participants in
the groups to which they were allocated, irrespective of treatment received, loss to follow-up,
or any protocol violations. In contrast, the per-protocol (PP) analysis population includes par-
ticipants who achieve an adequate measure of compliance with the treatment and with the trial
protocol [47]. The analysis population to be used in noninferiority trials has been the subject
of recent debate since neither the ITT nor PP populations are free from bias, and reliance on
either can increase the chance of falsely declaring noninferiority. In contrast to superiority tri-
als, in which ITT is preferred because it provides “a secure foundation for statistical tests” [47],
an ITT analysis can be biased towards noninferiority because of poor trial conduct diluting
the treatment effect, whereas a PP analysis can also be biased in either direction when
Fig 1. Illustration of the results of a noninferiority trial with a 6% margin of noninferiority (represented by the shaded area to the left of 6%), data from the
RIFAQUIN trial [5]. The findings for two drug regimens are illustrated by point estimates of efficacy surrounded by 90% confidence intervals from the per protocol
analysis. In this example, the 6-month regimen is noninferior to control because the upper bound of the confidence interval is less than the 6% margin of noninferiority.
However, the 4-month regimen is not noninferior to the control because the upper bound exceeds the margin of noninferiority.
https://doi.org/10.1371/journal.pmed.1002767.g001
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postrandomization exclusions from the analysis may be directly or indirectly related to treat-
ment allocation.
While a PP population has been recommended for noninferiority trials in the past [45,47],
its importance has been re-evaluated. FDA guidance no longer recommends PP (or as-treated)
analysis [41], even though the 2010 draft guidance accommodated one. There are limitations
in PP analyses, and proposed improvements include correcting for noncompliance and depen-
dent censoring using inverse probability weighting [48]. Current guidance suggests, instead, to
focus on ensuring trial quality to reduce the bias in the ITT analysis; consideration is also
given to multiple imputation as a way to counter bias due to attrition [41]. The 2017 adden-
dum (“estimands and sensitivity analysis in clinical trials” [49]) to the 1998 International
Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use
(ICH) E9 document (“statistical principles for clinical trials” [47]) goes beyond just specifica-
tion of an analysis population by recommending the use of an estimand as a framework for
aligning the target and method of estimation of a treatment effect with the objectives of the
clinical trial. The estimand “defines in detail what needs to be estimated to address a specific
scientific question of interest” [49] and includes four attributes: the population, the endpoint,
the specification of how to account for non-endpoint intercurrent events, and the population-
level summary. Practically, defining the primary estimand(s) of interest in the protocol before
the trial starts promotes clarity and coherence in how a treatment effect is estimated and how
it links back to the trial objective.
A further recent innovation has been the application of Bayesian methodology to the inter-
pretation of noninferiority trials. Presentation of the results as a simple binary statement as to
whether or not noninferiority has been achieved is of limited value because it gives no indica-
tion as to how close in efficacy the intervention is likely to be to the control and places undue
emphasis on the often arbitrary noninferiority margin. A much more informative approach is
to use a Bayesian analysis to provide the probability that the difference is less than some given
percentage, say 5% [50].
Role of adaptive trial designs
An adaptive clinical trial permits changes to various trial design features after trial initiation in
response to accruing data [51]. Although potential changes must be prespecified in the proto-
col so as not to undermine trial validity and integrity, adaptive trial designs are nevertheless
useful to account for uncertainty when a trial starts or for anticipating potential landscape
changes that may occur during the course of the trial. Most common are (i) the inclusion of
interim analyses that permit early stopping for overwhelming efficacy or lack of benefit when
evidence is sufficiently compelling with a smaller sample size than anticipated, and (ii) sample
size re-estimation during recruitment using a preplanned algorithm to ensure that the final
size will be adequate to answer the research question (particularly relevant when there is
uncertainty in the efficacy of the control arm).
When there are many potential combination regimens that might be considered for evalua-
tion, one might consider designs that select among multiple regimens either by stopping
recruitment to poorly performing arms after fixed-interval interim analyses (an example being
the multiarm multistage [MAMS] design [52,53]) or by adjusting randomization probabilities
to enroll more patients in more promising arms (Bayesian adaptive randomization [35]).
When the toxicity of a regimen is unknown, one might consider designs in which the eligibility
criteria are widened during the trial as more safety data accrue. This can, for instance, be per-
formed by starting to recruit patients with extensively drug-resistant TB (XDR-TB) because
few treatment options are available, then expanding to multidrug-resistant TB (MDR-TB) and
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DS-TB if safety thresholds are reached. Adaptations can, however, introduce bias in the esti-
mate of treatment effect or inflate the probability of a false positive result (type I error rate).
For example, in a two-stage multiarm trial in which only the intervention with the highest effi-
cacy in the first stage is taken forward to the second stage, the uncorrected estimate of efficacy
for this intervention at the end of the trial will be markedly biased and higher than the true effi-
cacy [54]. Thorough understanding of these aspects is critical for regulatory approval and con-
sideration in establishing WHO guidelines.
Strategy trials incorporating treatment stratification
Treatment stratification, the process of splitting a patient population into a small number of
groups who receive different treatments for the same disease based on a predictive biomarker,
is being widely studied in other disease areas [55–57]. In TB, it has long been recognized that
disease prognosis is affected by certain baseline factors such as pretreatment extent of cavita-
tion and viable counts of TB bacteria [58]. Wallace Fox sowed the seeds of stratified medicine
in 1981 [59] by noting that good prognostic factors could be used to tailor treatment duration.
The first trial incorporating treatment stratification had an enrichment design (one in which
eligibility criteria are restricted to or enriched for a particular subgroup of participants) that
evaluated a 4-month regimen with no new drugs in patients with noncavitary disease and cul-
ture negativity at 2 months. Before recruitment finished, the trial was stopped by the safety
monitoring committee because of an apparent increased risk for relapse in the 4-month arm
[7]. However, the completion of several large multicenter randomized trials in DS-TB showed
that a 4-month fluoroquinolone-based regimen may well be adequate for patients with nonca-
vitary disease [60]. Subsequent analyses describing an algorithm to more precisely identify
subgroups of patients with lower or higher risk of failure and relapse [61] have provided
important evidence to support the evaluation of treatment stratification in TB trials. These
data are only from rifampicin-containing regimens for DS-TB to date. Nevertheless, the prin-
ciples are likely also relevant for DR-TB, for which reducing duration for patients who do not
need it is even more important, given the high levels of toxicity of drugs and the longer dura-
tion of treatment [62].
Several trials are under development to evaluate new treatment strategies to assess different
durations, drug combinations, or drug dosages according to patient risk factors [63]. These
predictive biomarker validation trials are designed to “confirm” a stratification algorithm in a
randomized comparison against the standard-of-care strategy of a fixed duration regimen for
all patients [64]. They are distinct from more exploratory trials designed to “learn” or develop
and optimize the stratification algorithm [55]. Such trials tend to be smaller or have highly
adaptive designs and are also important to incorporate newer biomarkers into the stratification
algorithms, often to be evaluated in a subsequent larger confirmative trial. With appropriate
stratification, it is expected that it may be possible to target treatment strategies with superior
efficacy to standard of care, thereby avoiding many of the pitfalls of noninferiority trials.
The need for more pragmatic trials
In general, trials can be classified as explanatory (with the objective of evaluating the benefit an
intervention produces under ideal conditions, i.e., efficacy) or pragmatic (with the objective of
evaluating the benefit the treatment produces in routine clinical practice, i.e., effectiveness)
[65,66], although this is more of a continuum than a dichotomy [67]. Trials that are more
explanatory are needed to understand the efficacy and safety of a new drug under conditions
as ideal as possible. However, the context in which an explanatory trial is conducted can be so
far removed from routine practice that the results cannot readily be assumed to be transferable
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to clinical care. This is particularly the case when there are considerable changes in the land-
scape, as has been seen in DR-TB. The current acceptance of bedaquiline as a safe and effica-
cious drug in the treatment of MDR-TB is due less to the pivotal phase II background regimen
study [40], which initially led to WHO guidelines recommending bedaquiline only under cer-
tain conditions [68], than to the extensive nonrandomized data gathered outside of a trial set-
ting [15], mostly under program conditions. These programmatic data were influential in
bedaquiline becoming one of the three priority medicines in the revised 2018 WHO guidelines
for DR-TB [26], albeit based on low-quality evidence [69]. This reflects the way in which, in
the absence of pragmatic trials, WHO guidelines have been based almost exclusively on obser-
vational data that yield conditional recommendations based on low-quality evidence.
Pragmatic randomized trials with broader eligibility criteria, greater geographical spread,
use of programmatically relevant primary endpoints, use of best available standard of care as
control (see Table 2), and delivery and adherence strategies that are closer to “real-life” condi-
tions greatly increase generalizability of the results and lead to faster and more evidence-based
changes to policy and practice. Such pragmatic trials have been necessary in evaluating effec-
tive treatment strategies for HIV using previously licensed drugs (the START trial [70], for
example), and they will also be needed in TB. Pragmatic trials can also be embedded within
implementation programs to evaluate population-level effects of an intervention, an example
being the XTEND study, which was designed to evaluate the effect of the GeneXpert MTB/RIF
during implementation in South Africa [71]. Clearly, no single trial can address all relevant
questions about a given therapeutic intervention at one time, and pragmatic trials will be
invaluable for public health and policy decision-making purposes.
Conclusions
Just over 10 years ago, calls to action were published for innovations in drug development,
capacity building for TB trials, and execution of clinical trials of treatment for DR-TB [72–74].
Since November, 2007, 538 TB clinical trials have been posted on clinicaltrials.gov; 27 (5%) of
these have been for DR-TB. Between 1997 and 2007, these numbers were 127 and 4 (3%),
respectively. Although the objectives and quality of these trials vary hugely, these raw numbers
suggest that some progress has been made in clinical trial conduct.
The present review comes at a time when new drugs, new diagnostics, and new methods
make possible real transformation in TB treatment. Today, there are 8 and 6 new compounds
known to be in phase I and phase II clinical development, respectively (https://www.
newtbdrugs.org/pipeline/clinical), with many more in preclinical development. The advances
in clinical trial methodology that have been mentioned above alongside the promise of a vari-
ety of host-directed therapies [75] contrast starkly with the relative stagnation in treatment of
DS- and DR-TB since the 1990s. The delivery of new regimens to patients demands nimble-
ness in an endeavor that is long and cumbersome. Trials must be designed and implemented
in such a way that their relevance persists through completion. Careful choices of trial design,
comparator, sample size, biomarker stratification, estimands, analysis population(s), and non-
inferiority margin are critical from the outset. Changes in some of these characteristics after
trial initiation—through predefined adaptation and protocol amendments—must also be
entertained. Continued weighing of implications for time, cost, interpretation, and impact on
practice is essential; whether the trial is primarily explanatory or pragmatic is a decision based
on the balance among these competing priorities for any given trial. Transparency around
assumptions and factors influencing decision making is critical to interpretation by guidance
developers, practitioners, and patients. Consultation with external experts, including commu-
nity advisory boards, can facilitate this transparency.
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In conclusion, we strongly believe that TB treatment trials today should favor innovative
approaches that are able to produce high-quality evidence for high-quality, patient-centered
care that can be made accessible to all 10 million new TB patients, including the half-million
with DR-TB, each year.
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